ripekg:evaluation/RIPEA6DBDE4E81DF5F0FA |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:evidence-aggregation/RIPEA6DBDE4E81DF5F0FA |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-human-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-human-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-human-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-human-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-human-overall |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-inspectai-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-inspectai-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-inspectai-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:integrity-assessment-hypothesis/RIPEA6DBDE4E81DF5F0FA-inspectai-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:peer-comment/RIPEA6DBDE4E81DF5F0FA-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:peer-comment/RIPEA6DBDE4E81DF5F0FA-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:peer-comment/RIPEA6DBDE4E81DF5F0FA-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:peer-comment/RIPEA6DBDE4E81DF5F0FA-4 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:publication-details/RIPEA6DBDE4E81DF5F0FAA randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:registry-evidence/RIPEA6DBDE4E81DF5F0FA |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
rdf:type |
rdfs:Resource |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
rdf:type |
owl:Thing |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
rdf:type |
ripe:ResearchIntegrityAssessmentResearch integrity assessment |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
rdf:type |
tido:Case |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripe:assesses |
ripekg:work/10.1080%2F08989621.2022.2082290A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.01.2. Does the study have an associated expression of concern or other relevant post-publication notice? |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.0post-publication notices |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.01.3. Do other studies by the research team highlight causes for concern? |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0research-team-related concerns |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.01.1. Does the study have an associated retraction? |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.0retraction status |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.02.2. Are there concerns relating to the timing or absence of study registration? |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.0study registration |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0What is the overall integrity assessment of the study? |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0overall integrity assessment |
ripekg:retraction-notice/10278Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/10280Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/10282Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/12296Low-Dose Vitamin D Prevents Muscular Atrophy and Reduces Falls and Hip Fractures in Women after Stroke: A Randomized Controlled Trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16223Amelioration of Osteoporosis by Menatetrenone in Elderly Female Parkinson’s Disease Patients With Vitamin D Deficiency |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16225Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16226Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer’s disease |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16603Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16919Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/16920Beneficial Effect of Etidronate Therapy in Immobilized Hip Fracture Patients |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/18325Whole body vibration exercise improves body balance and walking velocity in postmenopausal osteoporotic women treated with alendronate: Galileo and Alendronate Intervention Trail (GAIT) |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/19693Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/20971Beneficial Effect of Etidronate Therapy in Chronically Hospitalized, Disabled Patients with Stroke |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/21506An Open-Label Trial Comparing Alendronate and Alphacalcidol in Reducing Falls and Hip Fractures in Disabled Stroke Patients |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/25238Anti-Fracture Efficacy of Risedronic Acid in Men |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/26473Efficacy of Bisphosphonates against Hip Fracture in Elderly Patients with Stroke and Parkinson Diseases: Meta-analysis of Randomized Controlled Trials |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/4480Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/5102Amelioration of Osteoporosis and Hypovitaminosis D by Sunlight Exposure in Hospitalized Elderly Women With Alzheimer's Disease: A Randomized Controlled Trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/5362Beneficial Effect of Intermittent Cyclical Etidronate Therapy in Hemiplegic Patients Following an Acute Stroke |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/5728Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/5729The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: A randomized controlled trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/6554Risedronate and Ergocalciferol Prevent Hip Fracture in Elderly Men with Parkinson Disease |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/6555Risedronate Therapy for Prevention of Hip Fracture After Stroke in Elderly Women |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/7882The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/9558Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/9565Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:retraction-notice/9569Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |
ripekg:study-design-evidence/RIPEA6DBDE4E81DF5F0FA |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA6DBDE4E81DF5F0FA |